Johnson & Johnson delivered a robust Q1 2026 with 6.4% operational sales growth, driven by strong performances across its innovative pharma and MedTech segments, and raised full-year guidance toward $100 billion revenue.
- Q1 revenue grew 6.4% annually, with Innovative Medicine up 7.4% and MedTech up 4.6%, reflecting broad-based momentum.
- Oncology led with 18% growth in DARZALEX and FDA approvals for TECVAYLI and CARVYKTI, expanding pipeline impact.
- Immunology sales surged 64%, driven by TREMFYA, and FDA approval of ICOTYDE positions the company for significant market share in immunology.
- MedTech’s cardiovascular segment showed strength in ablation and circulatory recovery, with innovative platforms like VARIPULSE and OMNYPULSE gaining traction.
- The company remains on track for $100 billion in 2026 revenue, with confidence in sustained double-digit growth through 2027.
Community Discussion